Odetiglucan is under clinical development by Hibercell and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Odetiglucan’s likelihood of approval (LoA) and phase transition for Follicular Lymphoma took place on 11 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 11 Mar 2022 increased Odetiglucan’s LoA and PTSR for Marginal Zone B-cell Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Odetiglucan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Odetiglucan overview

BTH-1677 is under development for the treatment of cutaneous melanoma, advanced indolent non-hodgkin's lymphoma, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), non-small cell lung cancer,  and patients with stage IV KRAS-mutated colorectal cancer, metastatic melanoma, metastatic breast cancer, metastatic triple negative breast cancer, pancreatic ductal adenocarcinoma and liver metastasis. The drug candidate is administered intravenously. It acts by targeting dectin-1, CR3, Fc gamma receptor and is being developed based on QuAD³ Platform. It is a soluble polysaccharide beta 1,3/1,6 glucan and is derived from the cell wall of the yeast Saccharomyces cerevisiae.

It was also under development for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, metastatic colorectal cancer, metastatic pancreatic adenocarcinoma and metastatic colorectal cancer (third-line therapy), chronic lymphocytic leukemia.

Hibercell overview

Hibercell is a biotechnology company that discovers and develops therapies for treatment of cancer. The company is investigating odetiglucan, an immune modulator candidate that enhances immune functions for treatment of metastatic breast cancer (mBC), pancreatic cancer and liver metastasis. It is also developing adoptive stress response modulator programs, HC-5404 for treatment of renal cell carcinoma, gastric cancer, and others advanced solid tumors; and HC-7366 to treat head and neck, Colorectal, and bladder cancer. Hibercell has developed AI and ML based QuAD3 platform that extracts phenotype and genomic data to understand patient’s outcome with adaptive stress response. The company operates discovery and development facility, clinical facility and laboratory in Ireland and the US. Hibercell is headquartered in New York, the US.

Quick View Odetiglucan LOA Data

Report Segments
  • Innovator
Drug Name
  • Odetiglucan
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Hibercell
  • Originator: Biothera Pharmaceutical
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.